Area of research
Hematology · Molecular Biology
Research interest
Research interests include Chronic Myeloid Leukemia Treatments, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research, and Acute Myeloid Leukemia Research.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Crenolanib is a selective type I pan-FLT3 inhibitor
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD